Genedrive Plc GDR

LSE · United Kingdom · Health Technology

GBp 1.200.00 (0.00%)

Market closed· Oct 1, 2026, 2:05 PM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Genedrive Plc GDR

LSE · United Kingdom · Health Technology

GBp 1.200.00 (0.00%)

Market closed· Oct 1, 2026, 2:05 PM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+26.32% · 6MFull-screen chart

Open GBp 1.24High GBp 1.25Low GBp 1.15Close GBp 1.20Volume 3.03M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: GBp 1.20
Day range: GBp 1.15 – GBp 1.25
52-week range: GBp 0.2100 – GBp 1.55
Volume: 3.03M
Market cap: £19.27M
Next earnings date: 2026-11-24
Avg. volume (1Y): 15.75M

Performance

1 week

-2.04%

1 month

-14.29%

3 months

-7.69%

6 months

+26.32%

Year to date

+37.14%

1 year

+380.00%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: United Kingdom
Exchange: LSE
Shares outstanding: 1.61B
ISIN: GB00B1VKB244
Beta: 3.25

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 09, 2026

genedrive CEO: NHS adoption and global expansion drive point-of-care testing push

genedrive PLC (AIM:GDR) CEO Dr Gino Miele spoke with Proactive's Stephen Gunnion about the diagnostic company's progress in rapid point-of-care genetic testing, growing NHS adoption and international expansion plans. Miele explained that Manchester-based genedrive has developed two CE-IVD-approved, NICE-recommended tests to help clinicians make safer prescribing decisions in emergency and acute care. The MT-RNR1 test identifies newborns at risk of irreversible hearing loss from aminoglycoside antibiotics, while the CYP2C19 test identifies stroke patients unlikely to respond well to the antipla

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.